Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
IT enters the final stretch before its November 3 earnings with a notable shift in the short book: what was an 11% short position as recently as last week has dropped to 9.6% of the free float, the biggest weekly reduction in the observable history of this note.
The short-interest unwind is the clearest change since the October 8 note flagged a stable, moderately elevated short book hovering near 8 million shares. That cushion has now been cut: shares short fell from roughly 8.06 million on October 8 to 6.92 million by October 13, a drop of 13.5% in the week. The ORTEX short score has also moved, easing from a tight 56 range to 54.1, its lowest reading in the 10-day window. That combination, fewer shares short and a softer short score, points to active covering rather than position drift. Borrow conditions confirm the picture: cost to borrow is a negligible 0.43%, availability remains at 1,813% of current short interest, and the 52-week low availability reading was 291%. There is no mechanical squeeze pressure here. Shorts who covered did so by choice.
Options positioning reinforces the less cautious mood. The put/call ratio has eased to 0.75, now running below its 20-day mean of 0.84 and about 0.6 standard deviations beneath it. That is a mild tilt toward calls, not an aggressive one, but it continues the directional shift that was already underway a week ago when the ratio dropped from above 1.18 through late September. The 52-week high for the PCR was 1.19, hit in mid-September. The current level is closer to the annual low of 0.35 than to that defensive peak. The stock itself is up 6.5% on the week and nearly 10% over the past month, closing at $196.96.
The Street's posture is broadly neutral, with recent target increases reflecting the stock's move rather than a change in thesis. BMO Capital lifted its target to $212 on October 13, maintaining a Market Perform rating. Morgan Stanley raised to $182 the prior week, also holding at Equal-Weight. UBS moved to $208 on October 5, keeping a Neutral view. The pattern is consistent: analysts are marking targets higher to stay current with the price but none are stepping up the rating. The consensus mean target is $189.54, which at the current price of $196.96 sits below where the stock is trading. Wells Fargo retains an Underweight with a $150 target. Goldman Sachs holds Neutral at $181. The bull case rests on strong renewal rates, a large addressable market, and shareholder returns. The bear case centres on contract value growth slowing, federal government headwinds, and pricing pressure from AI substitutes. The EV/EBITDA multiple has crept up over the past week but remains at 8.6x, and the PE at 12.3x is not stretched in isolation, though the deeply negative book value keeps the price/book at 15.6x.
The ownership register carries one notable structural development. The Vanguard Group filed a Schedule 13G/A in March 2026 disclosing a drop to 0.0% from a prior 12.43% stake, a significant exit by a major passive holder. Two separate Vanguard entities subsequently filed fresh 13G disclosures in April, together accounting for around 12.6% between Vanguard Capital Management (7.32%) and Vanguard Portfolio Management (5.26%), suggesting an internal restructuring of the holding rather than a true exit. Baron Capital remains the largest named holder at 12.0% as of June 30, having added 1.68 million shares in the period. AQR added 636,000 shares and Two Sigma added over 1 million. Independent Franchise Partners built from 6.53% to 8.34%. All 13D/G positions are as last disclosed and holders dropping below 5% may not file again. The recent insider filings are low-signal: the October 1 transactions carry a type code of "J" with no disclosed price, consistent with administrative transfers rather than open-market conviction. The 90-day net insider position is minus 7,082 shares for a net value of roughly minus $1.37 million, a modest net sale in the context of a stock at this price.
With earnings three weeks out and the short book now at its lightest level in months, the key question heading into November 3 is whether the contract value growth story and guidance tone can justify a stock trading above the consensus analyst target.
See the live data behind this article on ORTEX.
Open IT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
